CRBU / Caribou Biosciences stock soars after Pfizer buys stock priced at a 31% premium

Caribou Biosciences has plenty of money for the next year or so, and great data. Editas Medicine is far behind the competition with its lead programs. more_horizontal

BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharm more_horizontal

Here is how Caribou Biosciences, Inc. (CRBU) and DexCom (DXCM) have performed compared to their sector so far this year. more_horizontal

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compar more_horizontal

It's cumbersome and costly to manufacture complicated cell therapies. Caribou Biosciences and CRISPR Therapeutics have a better way of doing things. more_horizontal

Sudden and dramatic downturns in a company's share price can sometimes represent an incredible buying opportunity. Caribou Biosciences and AT&T may fa more_horizontal

Caribou Biosciences' results from the dose expansion portion of the phase 1 ANTLER study, using CB-010 for the treatment of patients with relapsed/ref more_horizontal

Shares of Caribou Biosciences Inc. CRBU, +4.90% tumbled 9.7% after hours on Thursday after the biopharma company said it had begun a $100 million shar more_horizontal